Adverum Biotechnologies Inc (FRA:AVU0)
€ 5.45 -0.05 (-0.91%) Market Cap: 116.09 Mil Enterprise Value: 40.31 Mil PE Ratio: 0 PB Ratio: 0.85 GF Score: 31/100

Adverum Biotechnologies Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 07:50PM GMT
Release Date Price: €193 (-5.39%)
Graig Suvannavejh
Goldman Sachs Group Inc., Research Division - Executive Director & Senior Equity Research Analyst

Okay, thank you, everyone, and welcome to 3:50 p.m. session on Day 3 of the Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I'm a senior analyst covering European and U.S. biopharma for the firm. It's my great pleasure to be hosting Adverum today for our fireside chat. We'll have about 40 minutes to get to know the company and ask questions, and I've got the pleasure of introducing 3 members of the senior management team, CEO, Leone Patterson; Chief Medical Officer, Aaron Osborne; and Chief Financial Officer, Thomas Leung.

So as we go into our fireside chat, let me first welcome Adverum to our conference. Hopefully, we can do this in-person next year out in, hopefully, sunny Southern California and sort of look forward to your participation in years to come.

For the audience, for those of you who may not know the Adverum story, maybe we can start by asking the management team and maybe, Leone, I'll pass it over to you, by just giving us kind

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot